Literature DB >> 20606628

C3 glomerulopathy: a new classification.

Fadi Fakhouri1, Véronique Frémeaux-Bacchi, Laure-Hélène Noël, H Terence Cook, Matthew C Pickering.   

Abstract

Several distinct pathological patterns of glomerular inflammation are associated with abnormal regulation of the complement system, specifically, with dysregulation of the alternative pathway of the complement system. However, these conditions share the pathological finding of complement C3 (C3) deposited within the glomerulus in the absence of substantial immunoglobulin. This finding has alerted us and others to the possible presence of genetic and acquired complement dysregulation in individual patients. This article summarizes our current understanding of the relationship between dysregulation of the complement system and glomerular inflammation. Here, we suggest that glomerular pathologies that are characterized by the isolated deposition of C3 could usefully be classified by the term C3 glomerulopathy. In our view, this classification would alert the pathologist and nephrologist to the importance of screening for acquired and genetic abnormalities in complement regulation. In the future, it could help to identify individuals who might benefit from therapeutic inhibition of the complement system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606628     DOI: 10.1038/nrneph.2010.85

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  27 in total

Review 1.  Systemic lupus erythematosus, complement deficiency, and apoptosis.

Authors:  M C Pickering; M Botto; P R Taylor; P J Lachmann; M J Walport
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

2.  Dense deposit disease: a variant of membranoproliferative glomerulonephritis.

Authors:  R Habib; M C Gubler; C Loirat; H B Mäiz; M Levy
Journal:  Kidney Int       Date:  1975-04       Impact factor: 10.612

3.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Authors:  Aude Servais; Véronique Frémeaux-Bacchi; Moglie Lequintrec; Rémi Salomon; Jacques Blouin; Bertrand Knebelmann; Jean-Pierre Grünfeld; Philippe Lesavre; Laure-Hélène Noël; Fadi Fakhouri
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

4.  Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN)

Authors:  M Levy; M C Gubler; M Sich; A Beziau; R Habib
Journal:  Clin Immunol Immunopathol       Date:  1978-08

5.  Continuing C3 breakdown after bilateral nephrectomy in patients with membrano-proliferative glomerulonephritis.

Authors:  E H Vallota; J Forristal; R E Spitzer; N C Davis; C D West
Journal:  J Clin Invest       Date:  1971-03       Impact factor: 14.808

6.  Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1.

Authors:  John J Neary; Peter J Conlon; David Croke; Anthony Dorman; Mary Keogan; Feng Yu Zhang; Jeffery M Vance; Margaret A Pericak-Vance; William K Scott; Michelle P Winn
Journal:  J Am Soc Nephrol       Date:  2002-08       Impact factor: 10.121

7.  Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes.

Authors:  Leendert A Trouw; Tom W L Groeneveld; Marc A Seelen; Jacques M G J Duijs; Ingeborg M Bajema; Frans A Prins; Uday Kishore; David J Salant; J Sjef Verbeek; Cees van Kooten; Mohamed R Daha
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

8.  Familial membranoproliferative glomerulonephritis type III.

Authors:  John Neary; Anthony Dorman; Eileen Campbell; Mary Keogan; Peter Conlon
Journal:  Am J Kidney Dis       Date:  2002-07       Impact factor: 8.860

Review 9.  Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.

Authors:  Christoph Licht; Veronique Fremeaux-Bacchi
Journal:  Thromb Haemost       Date:  2009-02       Impact factor: 5.249

Review 10.  Membranoproliferative glomerulonephritis.

Authors:  Bassam Alchi; David Jayne
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more
  124 in total

1.  Eculizumab for dense deposit disease and C3 glomerulonephritis.

Authors:  Andrew S Bomback; Richard J Smith; Gaetano R Barile; Yuzhou Zhang; Eliot C Heher; Leal Herlitz; M Barry Stokes; Glen S Markowitz; Vivette D D'Agati; Pietro A Canetta; Jai Radhakrishnan; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 8.237

2.  Eculizumab in Pediatric Dense Deposit Disease.

Authors:  Michiel J S Oosterveld; Mark R Garrelfs; Bernd Hoppe; Sandrine Florquin; Joris J T H Roelofs; L P van den Heuvel; Kerstin Amann; Jean-Claude Davin; Antonia H M Bouts; Pietrik J Schriemer; Jaap W Groothoff
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-27       Impact factor: 8.237

Review 3.  Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging.

Authors:  Joshua M Thurman; Natalie J Serkova
Journal:  Adv Chronic Kidney Dis       Date:  2013-11       Impact factor: 3.620

4.  C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Authors:  Nicholas R Medjeral-Thomas; Michelle M O'Shaughnessy; John A O'Regan; Carol Traynor; Michael Flanagan; Limy Wong; Chia Wei Teoh; Atif Awan; Mary Waldron; Tom Cairns; Patrick O'Kelly; Anthony M Dorman; Matthew C Pickering; Peter J Conlon; H Terence Cook
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

5.  Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Authors:  Caroline Rousset-Rouvière; Mathilde Cailliez; Florentine Garaix; Daniele Bruno; Daniel Laurent; Michel Tsimaratos
Journal:  Pediatr Nephrol       Date:  2014-01-10       Impact factor: 3.714

6.  C4d Staining in the Diagnosis of C3 Glomerulopathy.

Authors:  H Terence Cook
Journal:  J Am Soc Nephrol       Date:  2015-05-19       Impact factor: 10.121

7.  A rare case: childhood-onset C3 glomerulonephritis due to homozygous factor H deficiency.

Authors:  Krisztina Rusai; Vera Zaller; Agnes Szilagyi; Renate Kain; Zoltan Prohaszka; H Terence Cook; Christoph Aufricht; Klaus Arbeiter
Journal:  CEN Case Rep       Date:  2013-03-16

Review 8.  Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?

Authors:  Peter F Zipfel; Gunter Wolf; Ulrike John; Karim Kentouche; Christine Skerka
Journal:  Pediatr Nephrol       Date:  2011-06-14       Impact factor: 3.714

9.  A hybrid CFHR3-1 gene causes familial C3 glomerulopathy.

Authors:  Talat H Malik; Peter J Lavin; Elena Goicoechea de Jorge; Katherine A Vernon; Kirsten L Rose; Mitali P Patel; Marcel de Leeuw; John J Neary; Peter J Conlon; Michelle P Winn; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

10.  Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Authors:  Ozan Ozkaya; Hulya Nalcacioglu; Demet Tekcan; Gurkan Genc; Bilge Can Meydan; B Handan Ozdemir; M Kemal Baysal; Hasan Tahsin Keceligil
Journal:  Pediatr Nephrol       Date:  2014-01-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.